

## Addressing Barriers to Appropriate Basal Insulin Therapy Initiation and Management in T2D with Novel Insulin Technologies

### Basal Insulin Therapy: Historical Perspective



Ziegler AG, Danne T, Daniel C, Bonifacio E. 100 Years of insulin: Lifesaver, immune target, and potential remedy for prevention. *Med Perspective*. 2021;2:1120-1137.

### Barriers and Challenges with Basal Insulin Therapy in T2D



Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*. 2022;65:1925-1966.



Galdon Sanz-Pastor A, Enriquez AJ, Sanchez Bao A, Ampudia-Blasco FJ. Current barriers to initiating insulin therapy in individuals with type 2 diabetes. *Front. Endocrinol*. 2024;15:1366368.



Goldman JD, Eugenio AS, Gonzalez JS, Pang C, Tait J, Edelman S. Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin. *Clinical Diabetes*. 2023;41(2):244-257.



Rushforth B, McCrorie C, Glidewell L, Midgley E, Foy R. Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review. *Br J Gen Pract*. 2016 Feb;66(643):e114-27.

### Basis for Once Weekly Insulins



Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. *Diabetes* 2003;52:102–10.



Del Prato S, Marchetti P. Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones. *Diabetes Technol Ther*. 2004 Oct;6(5):719-31.



Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. *Diabetologia* 2004;47:31–9.



Karakasis P, Patoulias D, Pamporis K, et al. Efficacy and safety of once-weekly versus once-daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis. *Diabetes Obes Metab.* 2023;25(12):3648-3661.



Rosenstock J, Juneja R, Beals JM, Moyers JS, Ilag L, McCrimmon RJ. The basis for weekly insulin therapy: evolving evidence with insulin icodec and insulin efsitora alfa. *Endocr Rev.* 2024 May 7;45(3):379-413.

### Innovations on the Horizon: Emerging Trends in Basal Insulin Therapy Development

#### Pharmacology and Mechanisms of Action of Once Weekly Basal Insulins



Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterol.* 2007;132(6):2131–2157.



Heise T et al. Basal Insulin Fc (BIF), A Novel Insulin Suited For Once Weekly Dosing For The Treatment of Patients With Diabetes Mellitus. *J Endocrine Society.* 2021;5(Supp1):A329.



Moyers JS, Hansen RJ, Day JW, et al. Preclinical Characterization of Once Weekly Basal Insulin Fc (BIF). *J Endocrine Society.* 2021;5(Supp 1)A442.



Nishimura E, Kjeldsen T, Hubalek F, et al. Molecular and biological properties of insulin icodec, a new insulin analog designed to give a long half-life suitable for once-weekly dosing. *Diabetes.* 2020;69(Supp1):236-OR.



Niswender KD. Basal insulin: beyond glycemia. *Postgrad Med.* 2011;123:27–37.



Trevisan R, Conti M, Ciardullo S. Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes. *Diabetologia.* 2024.

## Innovations on the Horizon: Current Evidence and Clinical Considerations of Once Weekly Basal Insulins

### Insulin Icodec Clinical Data



Abuelazm M, Ibrahim AA, Khlidj Y, et al. Once-weekly insulin icodec versus once-daily long-acting insulin for type II diabetes: A meta-analysis of randomized controlled trials. *J Endocr Soc.* 2023;8(2):bvad177.



Bajaj HS, Aberle J, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5) : A randomized trial. *Ann Intern Med.* 2023;176(11):1476-1485.



Bajaj HS, Goldenberg RM. Insulin icodec weekly: A basal insulin analogue for type 2 diabetes. *touchREV Endocrinol.* 2023 May;19(1):4-6.



Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial. *JAMA.* 2023;330(3):228-237.



Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. *Lancet.* 2023;401(10392):1929-1940.



Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. *Lancet Diabetes Endocrinol.* 2023;11(6):414-425.



Pieber TR, Arfelt KN, Cailleateau R, et al. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial. *Diabetologia.* 2023;66(8):1413-1430.



Robinson S, Newson RS, Liao B, Kennedy-Martin T, Battelino T. Missed and Mistimed Insulin Doses in People with Diabetes: A Systematic Literature Review. *Diabetes Technol Therapeutics.* 2021; 23(12):844-856.



Rosenstock J, Bain SC, Gowda A, Jódar E, Liang B, Lingvay I, Nishida T, Trevisan R, Mosenzon O; ONWARDS 1 Trial Investigators. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. *N Engl J Med.* 2023;389(4):297-308.



Russell-Jones D, Babazono T, Cailleateau R, et al. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. *Lancet*. 2023;402(10413):1636-1647.



Shetty S, Suvarna R. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials. *Diabetes Obes Metab*. 2024;26(3):1069-1081.



Trevisan R, Conti M, Ciardullo S. Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes. *Diabetologia*. 2024. Epub ahead of print.



Vianna A, Vilsbøll T, Vinther S, Mu Y. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial. *JAMA*. 2023;330(3):228-237.



ONWARDS 1



ONWARDS 2




ONWARDS 3



ONWARDS 4



ONWARDS 5



ONWARDS 6

## Insulin Efsitora Clinical Data



Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care*. 2019;42(8):1593-1603.




Bue-Valleskey JM, Kazda CM, Ma C, et al. Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial. *Diabetes Care*. 2023;46(5):1060-1067.



Frias J, Chien J, Zhang Q, et al. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study. *Lancet Diabetes Endocrinol*. 2023 Mar;11(3):158-168.



Plum-Morschel L, Anderson LR, Hansen S, et al. Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus. *Clin Drug Investig*. 2023; 43(2):119–127. Published online 2023 Jan 11.



QWINT 1



QWINT 2



QWINT 3




QWINT 4



QWINT 5




## IcoSema Clinical Data



COMBINE 1



COMBINE 2



COMBINE 3



COMBINE 4

## Strategies for Advancing T2D Care: Initiation, Integration, Collaboration, and Patient Empowerment

### Guidelines & Recommendations



American Diabetes Association. Standards of Care in Diabetes—2023. *Diabetes Care*. 2023;46(suppl 1):S1-S291.



Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*. 2022;65:1925-1966.



ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes—2023. *Diabetes Care*. 2022;46(Supplement\_1):S140-S157.

### Patient Perspectives and Shared Decision-Making



Bomhof-Roordink H, Gärtner FR, Stiggelbout AM, et al. Key components of shared decision making models: a systematic review. *BMJ Open* 2019;9:e031763.



Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc*. 2011 Apr;86(4):304-314.



Kerr D, Rajpura JR, Namvar T. Evaluating patient and provider preferences for a once-weekly basal insulin in adults with type 2 diabetes. *Patient Prefer Adherence*. 2024;18:411-424.



Mayo Clinic Shared Decision-Making National Resource Center. 2019.



Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. *Diabetes Obes Metab*. 2011;13:144–149.



Wieringa TH, Rodriguez-Gutierrez R, Spencer-Bonilla G, et al. Decision aids that facilitate elements of shared decision making in chronic illnesses: a systematic review. *Systematic Rev*. 2019;8:121.